Profund Advisors’s Compass Therapeutics CMPX Stock Holding History

Profund Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$76.2K	Sell	73,294 -21,915	-23%	-$45.2K	﹤0.01%	1079
2026 Q2	$209K	Buy	95,209 +7,528	+9%	+$22.2K	0.01%	1061
2026 Q1	$464K	Buy	87,681 +30,435	+53%	+$176K	0.02%	577
2025 Q4	$307K	Buy	57,246 +40,778	+248%	+$188K	0.01%	851
2025 Q3	$57.6K	Buy	+16,468	New	+$52K	﹤0.01%	1045

Other funds holding CMPX

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return

Profund Advisors's CMPX Position: Q3 2026 in Review

Profund Advisors reduced its Compass Therapeutics (CMPX) stake by 23% in Q3 2026, selling an estimated $45.2K and leaving 73,294 shares worth $76.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

Profund Advisors first reported a position in CMPX in Q3 2025 and has held it in 5 quarters since. The position peaked at $464K in Q1 2026. 23 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

Profund Advisors held 73,294 shares of Compass Therapeutics worth $76.2K as of Q3 2026.
Profund Advisors sold 21,915 Compass Therapeutics shares in Q3 2026, an estimated $45.2K.
Compass Therapeutics made up ﹤0.01% of Profund Advisors's portfolio in Q3 2026, its #1079 holding.
Profund Advisors first reported a position in Compass Therapeutics in Q3 2025 and has held it in 5 quarters since.
Profund Advisors's Compass Therapeutics position peaked at $464K in Q1 2026.
23 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.